1. Tran LK, Anger KE, Dell’Orfano H, Rocchio MA, Szumita PM. Evaluation of Cost, Workflow, and Safety of Implementing a Vial Transfer Device for Ready-to-Mix Drugs at an Academic Medical Center. J Pharm Pract. 2020 Jul 8:897190020938195. doi: 10.1177/0897190020938195. Epubahead of print. PMID: 32638650.
2. van Zanten AR, Engelfriet PM, van Dillen K, et al. Importance of nondrug costs of intravenous antibiotic therapy. Crit Care. 2003; 7(6):R184-R190.
3. Trissel LA, Gentempo JA, Anderson RW, et al. Using a medium fill simulation to evaluate the microbial contamination rate for usp medium-risk-level compounding. Am J Health Syst Pharm. 2005; 62(3):285-288.
4. Maliekal J, Bertch KE, Witte KW. An update on ready-to-use intravenous delivery systems. Hosp Pharm. 1993;28(10):970–971, 5–7.
5. Hatoum HT, Witte KW, Biedron GT, et al. Microcosting method for small-volume injectables. Am J Hosp Pharm. 1986;43(2): 348-354.
6. Sherrin TP, Miller W, Latiolais CJ. Projecting staffing patterns from time study data in centralized intravenous admixture programs. Am J Hosp Pharm. 1972;29(12):1013-1019.
7. Rosselli D, Rueda JD, Silva MD, et al. Economic evaluation of four drug administration systems in intensive care units in Colombia. Value Health Reg Issues. 2014;5:20-24.
8. Lopez IC, Cuervo MS, Toha AC, et al. Impact of the implementation of vasoactive drug protocols on safety and efficacy in the treatment of critically ill patients. J Clin Pharm Ther. 2016;41(6): 703-710.
9. Sebastian G, Thielke TS. Work analysis of an admixture service. Am J Hosp Pharm
* Extrapolated yearly cost avoidance was measured by multiplying the number of documented yearly administrations by the difference in respective LCSP or RTU costs from V2B system costs.
** LCSP labor and equipment costs were based on previous time study data that evaluated the costs of preparing small volume injectables (SVI)
*** ISO 8536-4 standard IV spike